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Internal tandem duplication in Fms-like tyrosine kinase 3 (FLT3-ITD) isthe most frequent mutation observed in acute myeloid leukemia (AML)and correlates with poor prognosis. FLT3 tyrosine kinase inhibitors are
promising for targeted therapy. Here, we investigated mechanisms damp-
ening the response to the FLT3 inhibitor quizartinib, which is specific to the
hematopoietic niche. Using AML primary samples and cell lines, we
demonstrate that convergent signals from the hematopoietic microenviron-
ment drive FLT3-ITD cell resistance to quizartinib through the expression
and activation of the tyrosine kinase receptor AXL. Indeed, cytokines sus-
tained phosphorylation of the transcription factor STAT5 in quizartinib-
treated cells, which enhanced AXL expression by direct binding of a con-
served motif in its genomic sequence. Likewise, hypoxia, another well-
known hematopoietic niche hallmark, also enhanced AXL expression.
Finally, in a xenograft mouse model, inhibition of AXL significantly
increased the response of FLT3-ITD cells to quizartinib exclusively within a
bone marrow environment. These data highlight a new bypass mechanism
specific to the hematopoietic niche that hampers the response to quizar-
tinib through combined upregulation of AXL activity. Targeting this signal-
ing offers the prospect of a new therapy to eradicate resistant FLT3-ITD
leukemic cells hidden within their specific microenvironment, thereby pre-
venting relapses from FLT3-ITD clones. 
Introduction
The Fms-like tyrosine kinase 3 (FLT3) gene encodes a class III receptor tyrosine-
kinase (RTK) that is well expressed in hematopoietic stem progenitor cells (HSPC)
and strongly activates PI3K/AKT and MAPK pathways upon ligand binding.1
Internal tandem duplication (ITD) in FLT3 is one of the most frequent mutations
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ABSTRACT
found in acute myeloid leukemia (AML).2 Although the
FLT3-ITD mutation is a late event in leukemogenesis,3 it
is an important target for the disease.4 Indeed, FLT3-ITD
mutation is associated with a poor prognosis,5-7 and its
frequent occurrence at relapse suggests that FLT3-ITD
AML-initiating cells are key targets for long-lasting remis-
sion.
The FLT3-ITD mutation induces constitutive activity of
the receptor and a distinct pattern of activated signaling
pathways, the principal change being the activation of
the transcription factor STAT5.8 FLT3 tyrosine kinase
inhibitors (FLT3-TKI), which were developed as ATP-
competitive inhibitors, were initially tested in clinical tri-
als and produced variable benefits according to the dis-
ease heterogeneity. Among these treatments, quizartinib
(AC220), a FLT3-TKI specifically designed for FLT3,
induces a hematologic improvement in monotherapy
associated with approximately 50% of response.9
However, bone marrow (BM) blasts show little noticeable
cell apoptosis, but are associated with cell-cycle arrest
and terminal differentiation.10 Remissions are of short
duration, with the emergence of resistance related to sev-
eral mechanisms. Intrinsic mechanisms include the acti-
vation of bypass signaling pathways11 and activation loop
or gatekeeper mutations.4 Extrinsic mechanisms include
cell-to-cell interactions and secretion of cytoprotective
factors.12
AXL belongs to the TAM receptor family, which also
includes TYRO3 and MER.13 This RTK is activated by
homodimerization upon binding of its major ligand
growth arrest-specific 6 (GAS6).14 The GAS6/AXL path-
way contributes to cell growth, survival, invasiveness,
chemotaxis, apoptotic body clearance and immunity.15
AXL is ectopically- or over-expressed in a wide variety of
cancers and has always been associated with a poor prog-
nosis.16 We have reported resistance mechanisms involv-
ing AXL in chronic myeloid leukemia.17 In AML, AXL and
GAS6 levels of expression have been related to poor out-
comes.18,19 Paracrine AXL activation has been shown to
induce AML resistance to conventional chemotherapies
but also to FLT3-targeted therapy.20-23 However, no infor-
mation is available concerning the regulation of AXL
expression in the context of the AML-supportive
hematopoietic niche, which sustains AML resistance in
vivo.
Indeed, AXL expression and function have been shown
to be modulated by stress, nutrient deprivation and low
oxygen (O2) concentration in various solid tumors.14,24
These characteristics are quite similar to those within the
hematopoietic microenvironment of AML-initiating cells.
We show here that the hematopoietic microenvironment
educates AML cells to over-express AXL through a
cytokine-dependent STAT5 activation and low O2 con-
centration.
Methods
Cell culture, apoptosis and AXL, GAS6 and STAT5 gene
expression knock-down using shRNA
All cell lines (MV4-11, MOLM-13, MOLM-14, UT7-mpl,
K562, MS5, OP9, HS27a) were cultured in RPMI1640 or αMEM
medium, supplemented with 10% fetal calf serum (FCS), 2 mM
L-glutamine, 50 U/mL penicillin, and 50 μg/mL streptomycin.
Hypoxia was induced by incubating cells in a specific O2 cham-
ber (BioSpherix). The UT7-mpl cell medium was supplemented
with granulocyte-macrophage colony-stimulating factor (GM-
CSF, 2.5ng/mL, Diaclone, France), as previously described.25
UT7-mpl cells were pre-incubated for 18 hours (h) in the
absence of GM-CSF, before being activated by cytokines. Where
indicated, cells were cultured with vehicle or thrombopoietin
peptide (Sigma), interleukin (IL)-3 (Miltenyi Biotec), AXL-Fc
chimeric proteins (R&D Systems), AC220 (quizartinib) (LC lab-
oratories), R428 (Selleckchem), Ly294002, pimozide, JAK
inhibitor-I (Calbiochem/Merck). AC-4-130, a selective STAT5
inhibitor, was provided by JANPIX Ltd. (UK) under the license
from  Prof. Patrick Gunning’s group (University of Toronto,
Canada).26 Cell apoptosis was assessed using an APC-conjugated
Annexin V labeling detection kit coupled to flow cytometry and
BDFACSDIVATM software (BD Bioscience). For shRNA, viral
supernatants were titrated by serial dilutions and a FACS analy-
sis of GFP co-expressed marker in transduced K562 cells 72 h
later (Accuri C6, Beckton Dickinson). Lentiviruses were added
once, at a multiplicity of infection of 5-20 according to the cells.
Transduced cells were sorted 2-3 days after transduction using
GFP. Two different shRNA were used for all targets (Online
Supplementary Table S1). To confirm silencing, AXL, GAS6 or
STAT5 protein expressions were analyzed by immunoblotting.
Acute myeloid leukemia  patient and cord blood donor
biological samples 
Acute myeloid leukemia  samples were obtained from
patients at the University Hospital of Bordeaux and University
Hospital Paris Centre who gave written informed consent for
the use of biological samples for research, in accordance with
the Declaration of Helsinki. This allowed the collection of clini-
cal and biological data in an anonymized database, registered at
the “Commission Nationale de l’Informatique et des Libertés”
(authorization n. 915285) and “Comité de Protection des
Personnes” (authorization n. 2015-08-11D). For FLT3-ITD AML
patient samples, selection criteria were high leukemic burden
(blast cells level > 70%) and high FLT3-ITD/WT ratio (ITD/WT
> 0.5) (Online Supplementary Table S2). Bone marrow mononu-
clear cells were co-cultured with MS5 stromal cells in H5100
medium (Stem Cell Technologies), unless otherwise stated.
When indicated, AML cells were preincubated for 18 h in serum-
free IMDM medium in the absence of MS5 before being incu-
bated for 7 h in the presence of a cytokine cocktail that included
IL-3 (20 ng/mL), GM-CSF (10 ng/mL) and TPO (20 nM). Human
cord blood (CB) units were collected according to institutional
guidelines. Cord blood CD34+ were purified and cultured in a
four-cytokine-supplemented serum-free IMDM medium, as pre-
viously described.27
Further details about the methods used are available in the
Online Supplementary Appendix.
Results
Stromal protection of FLT3-ITD AML cells to quizartinib
correlates with STAT5 activation
We first confirmed the protective effect of three stro-
mal cell lines on MV4-11, MOLM-13 and MOLM-14
FLT3-ITD AML cell lines exposed to quizartinib (AC220),
an ATP-competitive FLT3- inhibitor. Co-culture of AML
cells with one human (HS27a) and two murine (OP9 or
MS5) stromal cells decreased apoptosis triggered by FLT3-
TKI treatment compared to AML cells cultured without
stroma (Figure 1A and Online Supplementary Figure S1A
and B). This decrease persisted at high AC220 concentra-
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tions (10-20 nM) (Online Supplementary Figure S1C) and
was not due to a decrease in active AC220 concentration
by the metabolism of stromal cells (Online Supplementary
Figure S1D). To investigate further the mechanism of such
protection, stromal/AML cell co-cultures were performed
with a transwell separating the two kinds of cells, thereby
avoiding cell-to-cell contact. Transwell-separated stromal
cells still protected FLT3-ITD AML cells from quizartinib-
induced apoptosis, but the protective effect was weaker
(Figure 1B), suggesting the involvement of both cell-to-
cell contact and diffusible factors. We then analyzed sig-
naling pathways in cells treated with AC220 in the pres-
ence or absence of stroma. Whereas AC220 treatment of
FLT3-ITD AML cell lines (MV4-11, MOLM-14) decreased
Y591FLT3, T202/Y204ERK, Ser473AKT and Y694/Y699 STAT5
phosphorylation in the absence of stroma, the presence of
co-cultured stromal cells (MS5, OP9, HS27A), along with
AC220 treatment, specifically sustained
Y694STAT5A/Y699STAT5B phosphorylation (hereafter
referred to as pYSTAT5) (Figure 1C and Online
Supplementary Figure S1E). STAT5 Tyr phosphorylation
was still conserved at higher AC220 concentrations
(Online Supplementary Figure S1F). 
Therefore, stromal protection of FLT3-ITD AML cells is
associated with an FLT3-ITD-independent conservation
of STAT5 tyrosine phosphorylation.
AXL and resistance to quizartinib in the hematopoietic niche
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Figure 1. Stromal cells protect MV4-11 cells from AC220-induced apoptosis and cor-
relate with enhanced STAT5 activation. (A) MV4-11 FLT3-ITD acute myeloid leukemia
(AML) cell line was incubated in the absence (Vehicle) or presence of AC220 (3 nM)
for 48 hours, without (None) or with the indicated murine (OP9 or MS5) or human
(HS27a) stromal cell lines. Cell apoptosis was determined by Annexin V/DAPI labeling
followed by flow cytometry analysis. (B) MV4-11 FLT3-ITD AML cell line was incubated
in the absence (Vehicle) or presence of AC220 (3 nM) for 48 h, without (None) or with
OP9 cells separated (Stroma TW) or not (Stroma) by transwells. Apoptosis induction
was determined as in (A). (C) MV4-11 cells were incubated in the absence (Vehicle)
or presence of AC220 (1 nM), without (none) or with OP9 stromal cells (Stroma) for
48 h. Upon cell lysis, immunoblot analysis of the indicated protein with β actin as a
loading control, each of protein-dedicated immunoblot without (none) or with (stro-
ma) OP9 co-culture was performed on the same membrane. Results shown are rep-
resentative of three experiments. Graphs show the mean±Standard Error of Mean of





AXL contributes to stromal cell-dependent FLT3-ITD
AML resistance to FLT3-TKI
To determine how STAT5 contributes to TKI-resistance
of AML cells by stromal cells, we looked for STAT5 target
genes in myeloid cells. We searched for STAT5 regulated
genes by conducting a comparative large-scale genome
expression analysis of STAT5 knocked-down (KD) and
control cells using normal human primitive CD34+ CD38–
HSPC. Among the top-ranked down-regulated transcripts
upon STAT5 KD, we looked for mediators that might be
involved in stromal protection. AXL was the only RTK
down-regulated in these STAT5 KD cells (Online
Supplementary Table S3) and was the only one reported in
resistance to treatment in AML.21,23 To examine the role of
AXL in cancer resistance, we investigated whether there
was a link  between STAT5-dependent AXL regulation,
stroma-dependent STAT5 tyrosine phosphorylation main-
tenance and stromal protection for AC220. We found that
AXL mRNA and protein were both decreased in STAT5
KD HSPC (Online Supplementary Figure S2A). Like HSPC,
STAT5 KD induced AXL loss in MV4-11 and MOLM-14
FLT3-ITD or UT7 FLT3 wt AML cell lines (Figure 2A and
Online Supplementary Figure S2B). STAT5 is encoded by
two highly similar genes, STAT5A and STAT5B, whose
combined KD led to cell death. However, STAT5A-
restricted KD did not affect AML cell survival; it allowed
us to perform rescue experiments. Silencing of STAT5A
followed by expression of either murine STAT5A or
murine STAT5B enhanced AXL expression, thus providing
evidence that both STAT5 regulated AXL expression
(Online Supplementary Figure S2B). Finally, we found that
stromal cells enhanced both STAT5 phosphorylation and
AXL expression in MV4-11 and MOLM-14 cells (Figure
2B). These activities were both prevented when cells were
incubated in the presence of the STAT5 inhibitor AC-4-
130  (Online Supplementary Figure S2C). Overall, these data
indicated that stroma supports STAT5 activation of AML
cells, which enhances AXL expression of AML cells.
We thus analyzed the role of AXL in AML cell survival
with a well-characterized and clinically investigated AXL-
TKI compound, R428.28 To determine whether AXL and
FLT3-ITD pro-survival activity were connected, we first
determined the minimal effective AC220 and R428 dose
to induce apoptosis after 48 h of incubation (Online
Supplementary Figure S2D). The minimal effective AC220
dose was 1-3 nM, depending on the FLT3-ITD AML cell
line, whereas for R428 it was 0.3 μM for all. Using these
doses, we observed that AXL and FLT3 co-inhibition trig-
gered additive apoptosis (MOLM-13) and even a weak
synergistic activity (MV4-11 and MOLM-14) as compared
to single drug treatment (Figure 2C). 
Next, we investigated whether such effects were
observed in primary AML blasts. In all primary AML sam-
ples tested, HS27a stroma induced upregulation of AXL
expression (AML#1, #2 in Figure 2D and Online
Supplementary Table S2). However, this increase did not
provide extra AML cell survival when AXL activity was
inhibited. Instead, AXL and FLT3 co-inhibition induced a
significantly stronger apoptosis than single drug treat-
ments on primary AML blasts cultivated ex vivo on stromal
cells (AML #3 to #9 in Figure 2E and Online Supplementary
Table S2).
AXL is activated through the binding of its ligand GAS6,
for which autocrine and paracrine activities have been
reported in various contexts, including AML. Although
both stromal and leukemic cells are known to secrete
GAS6, stromal secretion was 10- to 20-fold more abun-
dant than leukemia ones, as detected by species-specific
ELISA (Online Supplementary Figure S2E).29 We analyzed
the contribution of GAS6 to the protective activity of stro-
mal cells toward AC220-induced AML cell apoptosis.
Protection of FLT3-ITD AML cells by stromal cells was
significantly reduced yet was not suppressed in the pres-
ence of AXL-Fc, a well-known GAS6-neutralizing mole-
cule22 (Figure 2F). Moreover, GAS6-KD OP9 stromal cells
provided weaker protection than parental OP9 (Figure 2G
and Online Supplementary Figure S2F), confirming the
results observed with AXL-Fc. 
Taken together, using an AXL inhibitor (R428) or a
GAS6-neutralizing molecule (AXL-Fc) and genetically
engineered stromal cells (OP9 shGAS6), these results con-
firm that AXL activity contributes to the stromal protec-
tion of FLT3-ITD AML.
STAT5-activating cytokines up-regulate AXL expression
and activity 
Since AXL expression is associated with STAT5 activa-
tion, we wondered whether and how stroma activates
STAT5. We first analyzed GAS6 activity but did not detect
any STAT5 tyrosine phosphorylation upon GAS6 treat-
ment in AML cells. We therefore wondered whether
STAT5-activating cytokines, secreted by stromal cells,
could trigger AXL overexpression. Therefore, we first used
the UT7-mpl AML cell line (FLT3 wild type) which is
highly sensitive to GM-CSF and TPO for its growth and
survival.25 Both GM-CSF and TPO activated STAT5 and
enhanced AXL expression within a few hours (Figure 3A
and B). These cytokines are known to activate STAT5 by
binding to their receptors through subsequent activation
of JAK2 kinase. In the presence of the STAT5 inhibitor
pimozide (pi) or the JAK2 inhibitor-I (ji), GM-CSF and
TPO no longer up-regulated AXL expression, whereas
inhibition of the PI3K/AKT pathway by LY294002 (ly) had
no effect (Figure 3B). We further observed that AXL acti-
vation was also induced by GM-CSF and TPO in AML
cells, as assessed by Tyr779 AXL phosphorylation detec-
tion and by global Tyr phosphorylation in AXL immuno-
precipitates (Figure 3B and C). Similar results were
obtained using primary CB CD34+ HSPC in the presence
of interleukin (IL)-3 or TPO. However, this was not the
case with the FLT3 ligand, which did not activate STAT5
(Online Supplementary Figure S3A). These results indicated
that STAT5-activating cytokines can up-regulate both
AXL expression and activation in normal HSPC and FLT3
wild-type AML.
FLT3-ITD AML cells are known to co-express cytokine
receptors such as IL-3 and TPO receptors, whose activity
remains ill-defined.29,30 We wondered whether cytokines
could trigger AXL upregulation, specifically in FLT3-ITD
AML cells. Despite the presence of FLT3-ITD inhibitor
AC220, IL-3 sustained STAT5 phosphorylation (Figure
3D). This activation was correlated with an increase in
AXL protein expression (Figure 3E). Similarly, in primary
AML samples, an IL-3/GM-CSF/TPO cytokine cocktail
increased AXL RNA expression (AML#10-12 and #15-16
in Figure 3F and Online Supplementary Table S2) associated
with STAT5 activation (AML#10-14 in Figure 3G and
Online Supplementary Table S2).  
To unravel how STAT5 up-regulates AXL transcript lev-
els, we focused on the AXL genomic sequence. STAT5
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transcription factors bind to TTCN3GAA STAT-Response
Element (SRE) on their target genes. One SRE that is con-
served among species including rat, mouse and human
was identified within intron 16 and located at Chr19(+)
[41,725,104-41,767,672] (www.genome.ucsf.edu).
Oligonucleotide pull-down assays showed that this iden-
tified SRE was functional, since it bound STAT5 as effi-
ciently as the control canonical SRE (ONc) from the IRF1
promoter sequence (Online Supplementary Figure S3B).
Chromatin immunoprecipitation (ChIP) assays with
STAT5 antibodies showed that STAT5-activation trig-
gered binding to the AXL genomic sequence (Figure 3H).
Together with STAT5 binding, recruitment of RNAPolII to
the AXL gene was enhanced, as assessed by anti-RNAPolII
AXL and resistance to quizartinib in the hematopoietic niche
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Figure 2. STAT5 up-regulates AXL which
contributes to FLT3-ITD acute myeloid
leukemia (AML) cell survival. (A) MOLM-14
and MV4-11 cells were transduced with the
indicated shRNA encoding lentiviral vectors
and lysed three days later. Immunoblot
analysis of the indicated proteins was per-
formed with β actin as a loading control. (B)
MOLM-14 and MV4-11 cells were co-cul-
tured in the absence (-) or presence (+) of
OP9 stromal cells for 48 hours (h) before
being isolated and lysed. The indicated pro-
teins were analyzed by immunoblotting. (C)
MV4-11, MOLM-13 and MOLM-14 cells were
treated in the absence (Vehicle) or presence
of minimal effective (MV4-11, MOLM-14) or
suboptimal (MOLM-13) dose of AC220 (1
nM) and R428 (0.3 µM) or both (Combo) for
48 h. Apoptosis induction was determined
as in Figure 1. (D) Primary FLT3-ITD AML
blasts (n=2, AML#1-2) were cultured with-
out (-) or with (+) human stromal cells
(HS27a) for two days and lysed. Immunoblot
analysis of the indicated proteins was per-
formed with β actin as a loading control. (E)
Primary FLT3-ITD AML blasts (n=7, AML#3-
9) were co-cultured on MS5 stromal cells for
24 h, then co-incubated in the presence of
AC220 (1 nM), R428 (0.3 μM) or both for 48
h. Apoptosis induction was assessed by
Annexin V/DAPI labeling and flow cytometry
analysis. Results are from seven AML sam-
ples treated in independent experiments. (F)
MV4-11 cells were incubated with AC220 (1
nM), without (none) or with stromal cells
(OP9) added with Ctrl-Fc or AXL-Fc 
(1 μg/mL). Cell apoptosis was determined
as indicated in Figure 1. (G) MV4-11 cells
were incubated in the absence (Vehicle) or
presence of AC220 (3 nM), without (None)
or with OP9 stromal cells that express shCtrl
or shGAS6. Apoptosis induction was deter-
mined as described above. Graphs show the
mean±Standard Error of Mean of results of
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Figure 3. Activation of STAT5 up-regulates AXL gene expression and phosphorylation. (A) UT7-mpl acute myeloid leukemia (AML) cells were treated with GM-CSF (2.5
ng/mL) or TPO (20 nM) for the indicated time and lysed. Immunoblot analysis of the indicated proteins; HSP60 was used as a loading control. (B) UT7-mpl cells were
treated with GM-CSF (2.5 ng/mL) or TPO (20 nM) for the indicated time in the absence or presence of pimozide (pi, 2 μM), JAK inhibitor-I (ji, 1 μM) or Ly294002 (ly,
20 μM). Total cell lysates were analyzed by western blotting with the indicated antibodies. HSP60 was used as a loading control. (C) UT7-mpl cells were incubated with
(+) or without (-) TPO (20 nM) for one hour (h) before being lysed. AXL immunoprecipitates were prepared and analyzed by immunoblotting with the indicated antibodies.
(D and E) MOLM-14 or MV4-11 cells were pre-incubated with (+) or without (-) AC220 (3 nM) for 3 h before adding IL-3 (ng/mL, MOLM-14) or TPO (nM, MV4-11) at the
indicated concentration. Cells were incubated for 4 h before being lysed. (F and G) MS5 co-cultured AML primary blasts were maintained in serum-free medium without
stroma for 18 h before being incubated in the presence of a IL-3 (20 ng/mL)/GM-CSF (10 ng/mL)/TPO (20 nM) cytokine cocktail for 7 h and then lysed for protein (F,
n=6, AML#10-12 and 15-16) and mRNA (G, n=5, AML#10-14) purification. Immunoblot analysis of the indicated proteins using β actin or HSP60 as loading controls;
real-time quantitative polymerase chain reaction (RT-qPCR) quantification of AXL mRNA levels in cytokine-treated and untreated primary AML cells, normalized to
GAPDH expression, and expressed relative to untreated cells. (H and I) UT7-mpl cells were incubated with (+) or without (-) TPO (20 nM) for 30 minutes. Chromatin-
immunoprecipitation (IP) assays were performed using control immunoglobulins (IP IgG), STAT5 (IP STAT5) or RNA polymerase II (IP PolII) antibodies.
Immunoprecipitated DNA were analyzed by qPCR using primers spanning the conserved STAT5-responsive element of AXL gene sequence and expressed relative to






ChIP (Figure 3I). These data indicated that STAT5 binds to
the AXL gene and increases AXL promoter activity.
Taken together, these data indicated that STAT5 medi-
ates stroma-dependent AXL upregulation.
Low O2 concentration enhances AXL expression
In addition to stromal cells and cytokines, the
hematopoietic niche is also characterized by low O2 con-
centrations, which have been linked to AXL expression in
other cancer cells.24,31 We thus assessed the contribution of
low O2 levels (1% O2) in this model. Interestingly, hypoxia
enhanced AXL expression in both FLT3-ITD AML cell
lines and primary FLT3-ITD AML blasts (Figure 4A and
AML#17 in Figure 4B and Online Supplementary Table S2).
Several Hypoxia-Response Elements (HRE) have been
described within a 2.4 kb fragment of the AXL promoter.24
AXL transcript levels were thus assessed in hypoxic cul-
ture for both AML cell lines and primary AML blasts. In all
cells, hypoxia enhanced AXL RNA expression, thereby
indicating that O2 levels affect AXL expression (Figure 4C
and AML#18-20 in Figure 4D and Online Supplementary
Table S2).
As AXL contributed to FLT3-ITD AML cell survival in
normoxia (see Figure 2C), we then analyzed its involve-
ment in AML cell survival in hypoxia by using the AXL-
TKI R428. In the absence of stroma, R428-induced apop-
tosis was similar in hypoxia and normoxia. Conversely, in
the presence of stroma, R428 triggered much stronger
apoptosis under hypoxia (Online Supplementary Figure S4).
Overall, these data indicate that both low O2 concentra-
tions and STAT5-activating stromal cytokines, in addition
to GAS6, regulate AXL activity, thus mediating stronger
AXL-dependent protection of AML cells.
AXL mediates microenvironment-dependent resistance
of FLT3-ITD acute myeloid leukemia cells to AC220
treatment in vivo
Having shown that AXL mediates microenvironment-
dependent protection against quizartinib in vitro, we ana-
lyzed the contribution of AXL in vivo. To better investigate
the role of AXL on a long timescale, we generated stable
AXL KD FLT3-ITD AML cells through lentivirus-mediated
RNA interference (Online Supplementary Figure S5A). MV4-
11 shCtrl and MV4-11 shAXL cells were engineered to sta-
bly express the firefly luciferase gene. They were
xenografted by vein injection and leukemic cell engraft-
ment was analyzed by bioluminescence imaging (BLI). BLI
analysis did not evidence any significant difference in
AXL and resistance to quizartinib in the hematopoietic niche
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Figure 4. Low O2 concentration up-regulates AXL expression of FLT3-ITD acute myeloid leukemia (AML) cells. (A) MV4-11 cells were incubated for 48 hours (h) at 20%
or 1% O2 with or without MS5 stromal cells as indicated; MOLM-14 cells were incubated for 48 h at 20% or 1% O2 without stroma. Immunoblot analysis of the indicated
proteins was performed with β actin as a loading control. (B) Primary FLT3-ITD AML blasts (AML#17) were cultured with HS27a stromal cells for two days in normoxia
(20%) and hypoxia (1%). Samples were lysed at day zero and two days after growth on stromal cells. Immunoblot analysis of the indicated proteins was performed with
β actin as a loading control. (C) MV4-11 and MOLM-14 cells were incubated for 48 h at 20%, 3%, 1% O2. Real-time quantitative polymerase chain reaction (RT-qPCR)
analysis of AXL mRNA was performed. Results are normalized to GUSB expression and expressed relative to 20% O2 cultured cells. (D) Primary AML blasts (n=3,
AML#18-20) were incubated for 48 h at 20% and 3% O2. RT-qPCR analysis of AXL mRNA was performed as in (B). Graphs show the mean±Standard Error of Mean of




engraftment (timing, intensity) between MV4-11 shCtrl
and MV4-11 shAXL cells after seven days (Online
Supplementary Figure S5B). Half of the mouse cohort was
then treated with AC220 (5 mg/kg/day) by daily oral gav-
age for seven days, and response to treatment was
assessed by BLI at day 14. The tolerance to treatment was
checked by body weight control twice a week. A similar
bioluminescence indicative of tumor progression was
observed for MV4-11 shCtrl and MV4-11 shAXL cells in
the vehicle-treated cohort (Figure 5A and B). In contrast, a
significant decrease in total bioluminescent signal was
observed in response to AC220 in MV4-11 shAXL-
engrafted mice as compared to MV4-11 shCtrl-engrafted
animals  (P<0.01) (Figure 5B). To strengthen these data in
the specific setting of the microenvironment, another set
of experiments was performed with the same sequence of
conditioning, engraftment and treatment, but BLI was per-
formed upon treatment on femurs and tibias ex vivo at sac-
rifice. Again, a significant decrease in bioluminescence
was observed in bones from AC220-treated MV4-11
shAXL-engrafted mice compared to bones from MV4-11
shCtrl-engrafted animals, whereas no significant differ-
ence was observed between these two cohorts in the
absence of treatment (Figure 5C). Immunohistochemistry
analysis of BM was then performed to trace human cells
in the murine bone marrow tissue. Similar amounts of
human cells were detected in MV4-11 shCtrl- and shAXL-
injected mice in the absence of treatment (Figure 5D). In
the AC220-treated cohort, as expected, lower amounts of
human cells were detected in MV4-11 shCtrl-engrafted
BM than in the untreated cohort. Interestingly, almost no
human cells were detectable in MV4-11 shAXL-treated
animal samples, so BLI detection was under the threshold
in MV4-11 shAXL-treated animals (Figure 5D). Altogether,
these results show that AXL plays a key role in the AC220
response of FLT3-ITD AML cells in the specific context of
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2024 haematologica | 2019; 104(10)
Figure 5. AXL sustains FLT3-ITD acute myeloid leukemia (AML) cell
resistance to AC220 in the bone marrow hematopoietic niche. (A)
MV4-11 shCtrl-Luc and MV4-11 shAXL-Luc were injected at day 0
(106 cells/mouse) in the retro-orbital sinus vein of busulfan-pre-
treated NSG female mice. Mice were then treated or not with
AC220 (5 mg/kg/day body weight) from day 8 to day 14. At day 14,
animals (B) or bones (femurs, tibias), collected from the indicated
animals (C) were subjected to bioluminescent imaging (BLI). The
dotted line shows the median background signal indicating the
threshold for BLI sensitivity. Ph: photon; s: second; sr: steradian. (D)
Immunohistochemistry analysis of Human Leukocyte Antigen
expression in bone marrow  biopsies collected from the indicated
AML cell-injected mice in the absence or presence of AC220 at day





the hematopoietic niche, thus confirming our in vitro and
ex vivo data.
Next, we wondered whether the bone marrow niche
protection of FLT3-ITD AML cells is specific to the
hematopoietic niche conditions or if it would be similar in
other microenvironments. We thus evaluated the impact
of quizartinib on subcutaneous xenograft tumor growth
using control (MV4-11 shCtrl) and AXL KD (MV4-11
shAXL) AML cells. Subcutaneous implantation of these
cells into immunodeficient NSG mice resulted in solid
tumors without any difference between MV4-11 shCtrl
and MV4-11 shAXL cells (Online Supplementary Figure
S5C). After 21 days, when tumors reached 300-500 mm3,
half of the mouse cohort received AC220 by daily oral
gavage (5 mg/kg/day). This resulted in complete regres-
sion of the tumors after 14 days. We did not observe any
difference between MV4-11 shCtrl and MV4-11 shAXL in
terms of response to AC220 treatment regarding both the
kinetic and intensity of tumor regression (Online
Supplementary Figure S5C). The daily administration of
AC220 was ceased after full tumor regression, allowing
tumor regrowth 12 days after AC220 withdrawal. Again,
a similar progression was observed post-relapse between
MV4-11 shCtrl and MV4-11 shAXL-injected cohorts both
in time to relapse and in tumor volumes, thus confirming
the specific role of the hematopoietic niche (Online
Supplementary Figure S5C). Similar tumor weights at sacri-
fice confirmed these observations (Online Supplementary
Figure S5D). 
The absence of any difference in subcutaneous tumor
growth between MV4-11 shCtrl and MV4-11 shAXL-
injected animals shows that the instrumental role of AXL
in protecting AML cells against FLT3-targeted therapy in
vivo is specifically mediated by the hematopoietic niche.
Discussion
These findings show that the bone marrow hematopoi-
etic niche provides specific protection for FLT3-ITD AML
cells against quizartinib by multiple signaling pathways
converging to AXL upregulation and activation. In addi-
tion to the established role of the AXL canonical ligand
GAS6, the bone marrow niche enhances AXL expression
and the activity of AML cells through both STAT5-activat-
ing soluble factors and local hypoxic environment.
The microenvironment was already known to promote
AML cell resistance via several mechanisms such as
CXCL12-CXCR4 signaling,32 adhesion molecules such as
CD44 and selectins,33 vasculature by VEGF,34 and angiopoi-
etins/TIE2 signaling35 and well-reviewed by Brenner et al.36
More recently, FLT3-ligand and FGF1/2 were also identi-
fied as protective molecules against FLT3-TKI in vitro.37
Hypoxia, a key factor of the microenvironment, was also
reported to drive pro-tumoral signaling in AML via a
HIF1α/MIF/IL8 pathway that is also thought to play a role
in chronic lymphocytic leukemia survival.38 Stroma has
also been shown to sustain AML cell resistance to cytara-
bine via activation of the AXL receptor upon AML cell-
dependent education of stroma to secrete GAS6 in vitro.21
We now provide evidence that several microenvironment
messages converge to enhance AXL expression and activa-
tion, which sustain pro-survival signals to selectively pro-
tect FLT3-ITD AML cells from quizartinib treatment in
situ. Beyond demonstrating the value of AXL as a thera-
peutic target for AML burden, our data suggest a more
appealing approach in which prevention of AXL expres-
sion will be key to alleviating protection against treatment
of the leukemic initiating cells provided by their
hematopoietic niche. 
The role of cytokines and growth factors inside the
hematopoietic niche with regard to AML cell survival has
long been debated. TPO receptor expression level has
been shown in approximately 50% of AML patients.30 In
addition, primary human AML engrafts with higher effi-
cacy in mice in which human versions of CSF1, CSF2, IL3
and TPO genes are knocked-in into murine loci, suggest-
ing the central role of these cytokines.39 The IL-3 receptor
(CD123), whose expression carries a poor prognosis,40 is
thought to be a marker for AML-initiating cells41 and to be
closely related with FLT3-ITD mutation.42 Our data now
demonstrate a new survival mechanism provided by
STAT5/hypoxia in the upregulation of AXL. 
AXL expression is often up-regulated in solid tumors. Its
activation has been mostly observed under stress condi-
tions associated with metastatic disease or in situations
where tumor cells are under severe nutrient deprivation.
Knowledge about the extracellular messages that regulate
AXL expression is limited. However, interferon-α has
been reported to enhance AXL expression in monocytes
through a STAT1-dependent pathway, but the mechanism
by which this is achieved has not yet been investigated.43
Our results show for the first time that the AXL gene
exhibits a conserved SRE that binds cytokine-activated
STAT5 which up-regulates AXL gene expression through
enhanced recruitment of RNAPolII. All the cytokines stud-
ied (IL-3, GM-CSF and TPO) activated both STAT5A and
STAT5B, but we observed that STAT5A-selective knock-
down triggered massive AXL downregulation, whatever
the levels of STAT5B expression and activation (Dumas et
al., 2019, personal communications). These observations sug-
gest that STAT5A plays a dominant role in AXL regula-
tion, an observation that fits with major regulation by
STAT5A of other genes like HIF2α or PHD3 that promote
HSPC and leukemia cell maintenance, as we and others
have observed.44 Whether other STAT5-activating factors
also enhance AXL expression and contribute to tumorige-
nesis and resistance of other myeloid leukemia, non-
myeloid leukemia and/or solid tumors awaits further
investigation.
The current findings show that STAT5-activating factors
not only enhance AXL expression but also trigger AXL
activation. Indeed, TK receptors such as EGFR or VEGFR,
which activate Src kinases,45 and FLT3, were shown to
activate AXL.22 AXL also functions as a docking site for
non-receptor kinases such as Syk and Lyn,46 which could
be activated by hematopoietic niche signals. Whether
other kinases mediate AXL activation remains to be stud-
ied.
AXL expression is known to be modulated by O2 con-
centration in various solid tumors.24,31 Our present data
extend these observations to AML. Low O2 concentra-
tions are a well-known BM niche hallmark.47 Hypoxia was
shown to down-regulate FLT3 and FLT3-ITD signaling in
AML cells.48 Under such conditions, the PI3K/AKT path-
way was shown to sustain AML cell survival, rescuing
FLT3 activity,49 while AXL is known to activate PI3K/AKT
signaling in AML cells. We and others have previously
shown that cytokine-activated STAT5 enhances HIF2α
expression directly44 but also indirectly by inhibiting one
AXL and resistance to quizartinib in the hematopoietic niche
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of its destabilizers, the prolyl 4-hydroxylase domain pro-
tein 3 (PHD3) in both normal hematopoietic progenitors
and leukemic cells.27 Such activities might reinforce the
hypoxia-induced message coming directly from the
microenvironment and strengthen AXL overexpression. 
Finally, our data show that the hematopoietic niche pro-
vides selective signals regulating AXL expression. This
plays a pivotal role in the selective response of FLT3-ITD
AML cells to quizartinib within the specific location of the
bone marrow, where leukemic stem cells are well main-
tained. Our study suggests that, in addition to the dual
inhibition of AXL and FLT3 through TKI combination or a
dual TK inhibitor such as gilteritinib, targeting AXL
upstream signaling steps could be investigated in targeting
FLT3-ITD AML-initiating cells in the hematopoietic
niche.9,50 
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